Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 wild-type |
Therapy | Cytarabine + RO6839921 |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | acute myeloid leukemia | sensitive | Cytarabine + RO6839921 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RO6839921 and Cytosar-U (cytarabine) combination treatment demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration | Full reference... |